Literature DB >> 16825595

FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.

Yanqiao Zhang1, Xuping Wang, Charisse Vales, Florence Ying Lee, Hans Lee, Aldons J Lusis, Peter A Edwards.   

Abstract

OBJECTIVE: Based on the observation that Fxr-/- mice exhibit a proatherogenic lipoprotein profile, we investigated the role of FXR in the development of atherosclerosis. METHODS AND
RESULTS: Administration of a western diet to Fxr-/- mice or wild-type mice does not result in the development of significant atherosclerotic lesions. Consequently we generated Fxr-/- Ldlr-/- (DKO) mice and compared lesion development with Ldlr-/- mice. After 16 weeks on a Western diet, en face analysis of the aorta indicated that the male DKO mice had reduced atherosclerotic lesions as compared with Ldlr-/- mice. Plasma low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels were reduced by 40% to 50%, whereas triglyceride levels increased 4-fold in the male DKO mice. Finally, peritoneal macrophages freshly isolated from male DKO mice had reduced expression of CD36 mRNA and decreased neutral lipid accumulation, as compared with Ldlr-/- mice.
CONCLUSIONS: FXR deficiency in male, but not female, Ldlr-/- mice results in a reduction in the size of atherosclerotic lesions in the aorta. The reduction in atherosclerosis may result from a decrease in plasma low-density lipoprotein cholesterol, coupled with reduced expression of CD36 in macrophages of DKO mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825595     DOI: 10.1161/01.ATV.0000235697.35431.05

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  64 in total

1.  Effects of FXR in foam-cell formation and atherosclerosis development.

Authors:  Grace L Guo; Silvia Santamarina-Fojo; Taro E Akiyama; Marcelo J A Amar; Beverly J Paigen; Bryan Brewer; Frank J Gonzalez
Journal:  Biochim Biophys Acta       Date:  2006-10-14

Review 2.  Nuclear receptors and inflammatory diseases.

Authors:  Kun Wang; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2008-03-28

3.  Upregulation of decorin by FXR in vascular smooth muscle cells.

Authors:  Fengtian He; Qiuhong Zhang; Ramalinga Kuruba; Xiang Gao; Jiang Li; Yong Li; Wei Gong; Yu Jiang; Wen Xie; Song Li
Journal:  Biochem Biophys Res Commun       Date:  2008-06-02       Impact factor: 3.575

Review 4.  Microbial modulation of cardiovascular disease.

Authors:  J Mark Brown; Stanley L Hazen
Journal:  Nat Rev Microbiol       Date:  2018-01-08       Impact factor: 60.633

5.  Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.

Authors:  Liping Yang; David Broderick; Yuan Jiang; Victor Hsu; Claudia S Maier
Journal:  Biochim Biophys Acta       Date:  2014-06-18

6.  Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis.

Authors:  Qing Wu; Lulu Sun; Xiaomin Hu; Xuemei Wang; Feng Xu; Bo Chen; Xianyi Liang; Jialin Xia; Pengcheng Wang; Daisuke Aibara; Shaofei Zhang; Guangyi Zeng; Chuyu Yun; Yu Yan; Yicheng Zhu; Michael Bustin; Shuyang Zhang; Frank J Gonzalez; Changtao Jiang
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

Review 7.  Bile acids regulate cardiovascular function.

Authors:  Sandeep Khurana; Jean-Pierre Raufman; Thomas L Pallone
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

8.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

Authors:  Helen B Hartman; Stephen J Gardell; Chris J Petucci; Shuguang Wang; Julie A Krueger; Mark J Evans
Journal:  J Lipid Res       Date:  2009-01-27       Impact factor: 5.922

9.  Alterations of Cholesterol Metabolism in Inflammation-Induced Atherogenesis.

Authors:  David P Hajjar; Katherine A Hajjar
Journal:  J Enzymol Metab       Date:  2016-05-31

10.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.